Scynexis announces Phase 1 results for SCY-770 in kidney disease
SCYX•Scynexis said SCY-770 was well tolerated with a favorable safety profile at higher doses in a Phase 1 study. The company said a Phase 2 study in autosomal dominant polycystic kidney disease is on track to begin in Q4 2026.
1. Phase 1 results
Scynexis said SCY-770, an oral direct AMPK activator being developed to treat autosomal dominant polycystic kidney disease, was well tolerated with a favorable safety profile at higher doses in a Phase 1 study.
2. Phase 2 timing
The company said a Phase 2 study of SCY-770 in the disease is on track to initiate in Q4 2026.
